Mark Plavsic Sells 7,383 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares in the company, valued at $1,193,150.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Aura Biosciences Price Performance

AURA stock traded up $0.39 during trading on Wednesday, reaching $10.25. The company had a trading volume of 211,556 shares, compared to its average volume of 169,225. Aura Biosciences, Inc. has a 52 week low of $5.99 and a 52 week high of $12.35. The business has a 50 day moving average of $8.52 and a 200 day moving average of $8.00. The company has a market cap of $507.82 million, a P/E ratio of -5.44 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. Research analysts expect that Aura Biosciences, Inc. will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Aura Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AURA. Long Focus Capital Management LLC lifted its position in Aura Biosciences by 113.4% during the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares during the period. Levin Capital Strategies L.P. grew its stake in shares of Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after buying an additional 216,266 shares during the last quarter. Regency Capital Management Inc. DE increased its position in Aura Biosciences by 11.4% during the 1st quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after buying an additional 80,162 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Aura Biosciences by 51.4% during the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after buying an additional 48,549 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after acquiring an additional 41,711 shares in the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AURA has been the topic of several recent analyst reports. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. JMP Securities increased their price objective on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, September 13th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Aura Biosciences in a research note on Friday, September 13th. Finally, Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Aura Biosciences currently has an average rating of “Buy” and a consensus target price of $21.67.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.